New target for lung fibrosis discovered
Canadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Valneva inks $59m JE vaccine supply contract
/in News/by Thomas GabrielczykFrench vaccine specialist Valneva SE has inked a supply contract with the US Department of Defense for IXIARO its Japanese encephalitis (JE).
VTT turn waste into biofuels and chemicals
/in News/by Thomas GabrielczykResearchers at VTT Technical Research Centre of Finland Ltd have presented a new gasification-based technique to turn forest industry byproducts into transport fuels and chemicals.
Tissue specific tumour transition needs few cells
/in News/by Thomas GabrielczykGerman researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells.
Drug dissociates metastasis precursors in blood
/in News/by Thomas GabrielczykA team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated clusters of circulating […]
Policymakers take no action after ECJ mutagenesis ruling
/in News/by Thomas GabrielczykIn summer the European Court of Justice (ECJ) ruled that crops created by biological mutagenesis techniques fall under EU GMO legislation. Germanys government and the European Parliament see no need […]
Sandoz antiinfectives partner Ares Genetics gets fund
/in News/by Thomas GabrielczykJust in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed and novel antiinfectives that […]
AI provides face read-out of genetic diseases
/in News/by Thomas GabrielczykExperts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from facial images.
Endothelial disruption: From bench to bedside
/in News/by Thomas GabrielczykBio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency […]
Sanofi ends immuno-oncology discovery with Regeneron
/in News/by Thomas GabrielczykSanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab (REGN2810) as treatment for cutaneous squamous […]